Boothbay Fund Management’s Inhibrx INBX Stock Holding History

Boothbay Fund Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,600	Closed	-$3.37M	–	2258
2025 Q4	$3.37M	Buy	+42,600	New	+$2.9M	0.05%	421

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Boothbay Fund Management's INBX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 92,009 shares — an estimated $7.27M sold.

Boothbay Fund Management first reported a position in INBX in Q2 2024 and held it in 7 quarters. The position peaked at $7.27M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Boothbay Fund Management reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
Boothbay Fund Management sold 92,009 Inhibrx shares in Q1 2026, an estimated $7.27M.
Boothbay Fund Management first reported a position in Inhibrx in Q2 2024 and held it in 7 quarters.
Boothbay Fund Management's Inhibrx position peaked at $7.27M in Q4 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.